Taken together, these reports suggest that drugs inhibiting PARP-1 activity protect from neuroinflammation in MLD model via immunomodulation and direct neuroprotection and provide strong evidence for the utility of PARP-1 inhibitors in MLD and neuroinflammation. Here, PARP1 is linked to metachromatic leukodystrophy.